• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effects of Antiviral Treatment on Influenza-Related Complications over Four Influenza Seasons: 2006-2010

tetano

Editor, Senior Moderator
Curr Med Res Opin. 2016 Apr 7:1-35. [Epub ahead of print]
[h=1]Effects of Antiviral Treatment on Influenza-Related Complications over Four Influenza Seasons: 2006-2010.[/h] Spagnuolo PJ[SUP]1[/SUP], Zhang M[SUP]2[/SUP], Xu Y[SUP]3[/SUP], Han J[SUP]3[/SUP], Liu S[SUP]2[/SUP], Liu J[SUP]2[/SUP], Lichtveld M[SUP]2[/SUP], Shi L[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]PURPOSE:[/h] The objective of the study is to evaluate the effect of antiviral treatment, pre-existing diseases, and sociodemographic factors on the risk of influenza-related complications and healthcare utilization.
[h=4]METHODS:[/h] Case data were obtained from US MarketScan Research Databases. Cases had a clinical diagnosis of influenza between 2006 and 2010 and continuous healthcare insurance from 90 days before to 30 days after diagnosis. Logistic regression models were applied to explore the impact of antiviral treatment on complications and healthcare utilization. Modified generalized estimating equation regression models in propensity score matched samples were used to address the robustness of the study.
[h=4]RESULTS:[/h] Analyses included 1,557, 437 cases from four influenza seasons. In each season, 34.82%- 43.42% of patients received antiviral treatment, mostly oseltamivir. On average, 1.86% of patients were hospitalized, 9.56% visited the emergency room and 41.14% made ≥2 outpatient visits. The incidence of complications ranged from 17.62 to 19.67 per 100 patient-months. The relative risk of complications was increased in patients aged 0-4 years and those with pre-existing diseases, including asthma, Parkinson's disease, and cystic fibrosis. Overall, patients receiving antiviral treatment had an 11% reduction in the risk of complications. Among oseltamivir-treated patients, the risk of complications was significantly reduced by 81% in those treated ≤two days after diagnosis compared with later. Antiviral treatment significantly reduced the risk of hospitalization, emergency room visits and need for ≥2 outpatient visits by 29%, 24% and 11%, respectively. Propensity score matching method improved the strength of the study.
[h=4]CONCLUSIONS:[/h] Early treatment with antivirals, and specifically oseltamivir, significantly reduced the risk of influenza-related complications and healthcare utilization. However, lacking information about diseases severity and the time from onset of symptoms to fulfillment of a prescription may bias the outcomes.


[h=4]KEYWORDS:[/h] Influenza; antiviral; claims database; complications; oseltamivir

PMID: 27052817 [PubMed - as supplied by publisher]
 
Back
Top Bottom